Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Kidney Neoplasms Clinical Trial

Official title:

Treatment Patterns With Targeted Therapies in Metastatic Renal Cell Carcinoma (mRCC) in Sweden - A Retrospective Analysis of Data From National Registries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04669366
• Other study ID #: A6181234
• Secondary ID: RENCOMP3
• Status: Completed
• Start date: January 20, 2021
• Est. completion date: July 31, 2021

Study information

• Verified date: September 2021
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1095
• Est. completion date: July 31, 2021
• Est. primary completion date: July 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. all patients aged = 18 years with at least one filled prescription of an oral targeted therapy relevant for treating mRCC registered in the Swedish Prescribed Drug Register (PDR) between July 1st 2005 and June 30th 2020. The Anatomical Therapeutic Chemical (ATC) codes for the oral drugs relevant for treating mRCC are the following: L01XE04 (sunitinib), L01XE05 (sorafenib), L01XE11 (pazopanib), L01XE17 (axitinib), L01XE10 (everolimus), L01XE26 (cabozantinib), L01XE34 (tivozantib), L01XE29 (lenvatinib).

2. The patients identified in the PDR that also are identified in the SCR with the International Classification of Diseases and Related Health Problems (ICD)-7 diagnosis codes I800 or I809 and ICD-10 codes C64.0 and C64.9 from January 1st 2000 until December 31st 2019;excluding ICD-7 code I801 (cancer of the renal pelvis) will be included in the analysis set.

Exclusion Criteria:

Patients with ICD-7 code I801 will be excluded

Related Conditions & MeSH terms

• Kidney Neoplasms

Intervention

Drug:
• sunitinib
As provided in real world
• axitinib
As provided in real world

Locations

Country	Name	City	State
Sweden	Pfizer Innovations AB	Sollentuna

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to treatment discontinuation in first line sunitinib patients	Time to treatment discontinuation in first line sunitinib patients. Time to event measure with timeframe 0 - 180 months from treatment initiation.	July 1st 2005 to December 31th 2019
Secondary	Overall survival (OS) for first line patients with sunitinib	Overall survival in first line sunitinib patients. Time to event measure with time frame 0 - 180 months from treatment initiation.	July 1st 2005 to December 31th 2019
Secondary	Time to treatment discontinuation in second line axitinib patients	Time to treatment discontinuation in first line sunitinib patients. Time to event measure with timeframe 0 - 180 months from treatment initiation.	July 1st 2005 to December 31th 2019
Secondary	Overall survival (OS) for second line patients with axitinib	Overall survival in second line axitinib patients. Time to event measure with time frame 0 - 180 months from treatment initiation.	July 1st 2005 to December 31th 2019

External Links

•   To obtain contact information for a study center near you, click here.